Paula Green Sells 282 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 282 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $44.90, for a total transaction of $12,661.80. Following the sale, the senior vice president now owns 133,433 shares in the company, valued at $5,991,141.70. The trade was a 0.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Paula Green also recently made the following trade(s):

• On Friday, December 6th, Paula Green sold 860 shares of Twist Bioscience stock. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00.
• On Monday, November 11th, Paula Green sold 1,347 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $64,656.00.
• On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $246,147.40.
• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $143,025.10.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST traded up $0.33 during midday trading on Thursday, reaching $49.23. The stock had a trading volume of 486,846 shares, compared to its average volume of 939,671. The stock has a 50-day moving average of $45.51 and a 200-day moving average of $46.72. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of -13.68 and a beta of 1.82. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90.

Wall Street Analysts Forecast Growth

Several brokerages have commented on TWST. Barclays dropped their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Evercore ISI raised their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird upped their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. TD Cowen reiterated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Scotiabank upped their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TWST. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience during the 3rd quarter valued at about $34,000. Signaturefd LLC lifted its position in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in Twist Bioscience during the second quarter valued at approximately $61,000. Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience during the 3rd quarter valued at approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after acquiring an additional 381 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.